Recombinant Human CLEC12A/MICL/CLL-1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02358P-100UG
Human CLEC12A on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human CLEC12A/MICL/CLL-1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02358P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human CLEC12A/MICL/CLL-1 Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains His65-Ala265. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q5QGZ9 |
Target Symbol | CLEC12A/MICL/CLL-1 |
Synonyms | MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2 |
Species | Human |
Expression System | HEK293 |
Tag | N-hFc |
Expression Range | His65-Ala265 |
Mol. Weight | The protein has a predicted MW of 50.9 kDa. Due to glycosylation, the protein migrates to 68-73 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human CLEC12A, hFc Tag at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Biotinylated Anti-CLEC12A Antibody, hFc Tag with the EC50 of 20.2ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. |